RxDoctor Payments DataLook up a doctor →

Paul Barr, MD

Hematology · Rochester, NYNPI 1407946460

Payments from drug & device makers

$47,286,313in general payments, 2019–2025

Across 442 payments — averaging $106,983 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$41.9M
  • Astrazeneca UK Limited$2.2M
  • AbbVie$824K
  • Eli Lilly$807K
  • Pharmacyclics LLC, An Abbvie Company$559K
  • Beigene, Ltd.$430K
  • plus $583K from 22 others
$136,196in research payments, 2019–2025

Across 3 payments — averaging $45,399 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$136K
  • AbbVie$40

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$47,286,313 in reported general payments places this provider in the 95th percentile of 157 hematology providers in New York.

See all hematology providers in New York

Medicare billing

Part B allowed, 2024
$41,217
Medicare patients
145
Services billed
500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →